ARVN
Arvinas, Inc. NASDAQ Listed Sep 27, 2018$8.75
+0.81%
vs $8.68
Mkt Cap $564.6M
52w Low $6.32
29.7% of range
52w High $14.51
50d MA $8.09
200d MA $10.62
P/E (TTM)
60.7x
EV/EBITDA
-40.4x
P/B
1.3x
Debt/Equity
0.0x
ROE
-18.6%
P/FCF
-2.1x
RSI (14)
62.30
ATR (14)
$0.38
Beta
1.98
50d MA
$8.09
200d MA
$10.62
Avg Volume
897.7K
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766 an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut.
5 Science Park · New Haven, CT 06511 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug 4, 2026 | BMO | -0.37 | 2.58 | +789.6% | 8.06 | +3.3% | +11.7% | -6.7% | +3.3% | — | — | — |
| May 12, 2026 | BMO | -0.95 | -0.90 | +5.3% | 9.66 | +1.8% | -0.9% | +3.1% | -4.6% | -3.6% | -3.3% | — |
| Feb 24, 2026 | BMO | -0.55 | -1.10 | -100.0% | 12.30 | -7.9% | +0.6% | +7.5% | +0.6% | -0.8% | +0.9% | — |
| Nov 5, 2025 | BMO | -0.75 | -0.48 | +36.0% | 9.54 | -1.2% | +0.3% | +4.5% | +6.3% | +5.3% | +0.2% | — |
| Aug 6, 2025 | BMO | -0.87 | -0.84 | +3.4% | 7.61 | -6.4% | -15.5% | -3.0% | +0.8% | +4.8% | +3.0% | — |
| May 1, 2025 | BMO | -0.86 | 1.14 | +232.6% | 9.62 | -33.9% | -24.8% | +6.8% | -1.2% | -8.9% | -4.0% | — |
| Feb 11, 2025 | BMO | -1.07 | -0.63 | +41.1% | 18.97 | -1.3% | -6.8% | +1.5% | -1.6% | +3.6% | +1.9% | — |
| Oct 30, 2024 | BMO | -0.88 | -0.68 | +22.7% | 27.50 | +0.7% | +0.6% | -4.4% | +1.8% | -0.4% | +0.4% | — |
| Jul 30, 2024 | BMO | -0.72 | -0.49 | +31.9% | 27.78 | +4.0% | -2.5% | +1.6% | -2.7% | -3.5% | -3.6% | — |
| May 7, 2024 | BMO | -1.48 | -0.97 | +34.5% | 32.26 | +0.4% | +6.4% | -5.7% | -1.3% | -1.6% | +0.4% | — |
| Feb 27, 2024 | BMO | -1.33 | -2.53 | -90.2% | 48.79 | +0.0% | -1.6% | -4.3% | +0.1% | +2.9% | -1.8% | — |
| Nov 7, 2023 | BMO | -1.52 | -1.18 | +22.4% | 16.93 | +1.0% | +5.1% | -7.2% | -8.2% | -1.1% | +10.7% | — |
| Aug 8, 2023 | BMO | -1.67 | -1.25 | +25.1% | 23.34 | +3.2% | +4.1% | -1.9% | +3.8% | +0.7% | +0.7% | — |
| May 5, 2023 | BMO | -1.46 | -1.54 | -5.5% | 23.51 | +2.0% | +7.6% | -2.5% | -1.9% | +0.0% | -5.4% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug 4 | Wells Fargo | Downgrade | Overweight → Equal Weight | — | $8.06 | $8.33 | +3.3% | +11.7% | -6.7% | +3.3% | +0.8% | — |
| Mar 19 | BTIG | Maintains | Buy → Buy | — | $10.89 | $10.87 | -0.2% | +2.6% | -2.1% | -5.7% | -0.3% | +6.1% |
| Mar 19 | Citigroup | Maintains | Buy → Buy | — | $10.89 | $10.87 | -0.2% | +2.6% | -2.1% | -5.7% | -0.3% | +6.1% |
| Mar 5 | Citigroup | Maintains | Buy → Buy | — | $13.76 | $13.72 | -0.3% | -0.3% | -0.9% | -1.7% | +3.4% | -2.5% |
| Feb 25 | Wedbush | Maintains | Neutral → Neutral | — | $12.37 | $12.98 | +4.9% | +7.5% | +0.6% | -0.8% | +0.9% | -0.2% |
| Feb 25 | Piper Sandler | Maintains | Overweight → Overweight | — | $12.37 | $12.98 | +4.9% | +7.5% | +0.6% | -0.8% | +0.9% | -0.2% |
| Feb 25 | Evercore ISI | Maintains | Outperform → Outperform | — | $12.37 | $12.98 | +4.9% | +7.5% | +0.6% | -0.8% | +0.9% | -0.2% |
| Jan 6 | Citigroup | Upgrade | Neutral → Buy | — | $11.17 | $12.74 | +14.1% | +5.9% | +4.9% | -1.9% | -0.9% | +0.7% |
| Dec 17 | Barclays | Maintains | Overweight → Overweight | — | $11.90 | $12.20 | +2.5% | -1.5% | -3.8% | +3.5% | +5.5% | -1.1% |
| Nov 10 | Stephens & Co. | Maintains | Overweight → Overweight | — | $10.63 | $10.80 | +1.6% | +5.3% | +0.2% | -7.1% | -2.8% | +4.4% |
| Nov 6 | Wells Fargo | Maintains | Overweight → Overweight | — | $9.57 | $9.71 | +1.5% | +4.5% | +6.3% | +5.3% | +0.2% | -7.1% |
| Nov 6 | Barclays | Maintains | Overweight → Overweight | — | $9.57 | $9.71 | +1.5% | +4.5% | +6.3% | +5.3% | +0.2% | -7.1% |
| Oct 30 | BTIG | Maintains | Buy → Buy | — | $9.59 | $9.88 | +3.0% | +3.5% | +2.1% | -4.1% | -1.9% | +0.3% |
| Oct 15 | Goldman Sachs | Downgrade | Neutral → Sell | — | $9.41 | $8.80 | -6.5% | +0.5% | +2.3% | -1.7% | +2.1% | -0.6% |
| Sep 18 | Stephens & Co. | Maintains | Overweight → Overweight | — | $7.61 | $7.82 | +2.8% | +1.4% | -2.6% | +0.1% | +0.0% | +2.7% |
| Sep 18 | BTIG | Maintains | Buy → Buy | — | $7.61 | $7.82 | +2.8% | +1.4% | -2.6% | +0.1% | +0.0% | +2.7% |
| Aug 7 | Wells Fargo | Maintains | Overweight → Overweight | — | $6.43 | $6.64 | +3.3% | -3.0% | +0.8% | +4.8% | +3.0% | +4.4% |
| Aug 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.43 | $6.64 | +3.3% | -3.0% | +0.8% | +4.8% | +3.0% | +4.4% |
| Aug 7 | Guggenheim | Maintains | Buy → Buy | — | $6.43 | $6.64 | +3.3% | -3.0% | +0.8% | +4.8% | +3.0% | +4.4% |
| Jun 2 | Leerink Partners | Downgrade | Outperform → Market Perform | — | $7.20 | $6.74 | -6.4% | +1.8% | -4.5% | -0.7% | -0.4% | +8.8% |
| May 15 | UBS | Maintains | Buy → Buy | — | $6.07 | $6.11 | +0.7% | +3.1% | +3.7% | +0.6% | +1.7% | -5.9% |
| May 9 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $6.81 | $6.78 | -0.4% | -2.9% | -1.4% | -3.5% | -3.5% | +3.1% |
| May 5 | Truist | Downgrade | Buy → Hold | — | $7.72 | $7.50 | -2.8% | -1.2% | -8.9% | -4.0% | +2.1% | -2.9% |
| May 5 | BMO Capital | Maintains | Outperform → Outperform | — | $7.72 | $7.50 | -2.8% | -1.2% | -8.9% | -4.0% | +2.1% | -2.9% |
| May 5 | Citigroup | Maintains | Neutral → Neutral | — | $7.72 | $7.50 | -2.8% | -1.2% | -8.9% | -4.0% | +2.1% | -2.9% |
| May 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.23 | $7.29 | +0.8% | +6.8% | -1.2% | -8.9% | -4.0% | +2.1% |
| May 2 | Wells Fargo | Maintains | Overweight → Overweight | — | $7.23 | $7.29 | +0.8% | +6.8% | -1.2% | -8.9% | -4.0% | +2.1% |
| May 2 | Piper Sandler | Maintains | Overweight → Overweight | — | $7.23 | $7.29 | +0.8% | +6.8% | -1.2% | -8.9% | -4.0% | +2.1% |
| May 2 | Jefferies | Downgrade | Buy → Hold | — | $7.23 | $7.29 | +0.8% | +6.8% | -1.2% | -8.9% | -4.0% | +2.1% |
| May 2 | Guggenheim | Maintains | Buy → Buy | — | $7.23 | $7.29 | +0.8% | +6.8% | -1.2% | -8.9% | -4.0% | +2.1% |
| May 2 | Goldman Sachs | Maintains | Neutral → Neutral | — | $7.23 | $7.29 | +0.8% | +6.8% | -1.2% | -8.9% | -4.0% | +2.1% |
| May 2 | Barclays | Maintains | Overweight → Overweight | — | $7.23 | $7.29 | +0.8% | +6.8% | -1.2% | -8.9% | -4.0% | +2.1% |
| Apr 17 | Goldman Sachs | Maintains | Neutral → Neutral | — | $7.65 | $7.74 | +1.2% | +12.4% | +1.7% | +2.2% | +1.5% | +0.8% |
| Apr 9 | Truist | Maintains | Buy → Buy | — | $6.19 | $6.01 | -2.9% | +8.7% | -1.6% | +5.0% | +6.5% | +2.4% |
| Apr 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.56 | $6.32 | -3.7% | -2.9% | -2.8% | +8.7% | -1.6% | +5.0% |
| Mar 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.55 | $8.55 | +0.0% | -1.4% | +3.2% | -3.2% | +3.3% | +3.4% |
| Mar 13 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $9.03 | $8.90 | -1.4% | -5.3% | -1.4% | +3.2% | -3.2% | +3.3% |
| Mar 13 | Guggenheim | Maintains | Buy → Buy | — | $9.03 | $8.90 | -1.4% | -5.3% | -1.4% | +3.2% | -3.2% | +3.3% |
| Mar 12 | BofA Securities | Maintains | Buy → Buy | — | $8.30 | $8.39 | +1.1% | +8.8% | -5.3% | -1.4% | +3.2% | -3.2% |
| Mar 12 | BMO Capital | Maintains | Outperform → Outperform | — | $8.30 | $8.39 | +1.1% | +8.8% | -5.3% | -1.4% | +3.2% | -3.2% |
| Mar 12 | Wells Fargo | Maintains | Overweight → Overweight | — | $8.30 | $8.39 | +1.1% | +8.8% | -5.3% | -1.4% | +3.2% | -3.2% |
| Mar 12 | Wedbush | Downgrade | Outperform → Neutral | — | $8.30 | $8.39 | +1.1% | +8.8% | -5.3% | -1.4% | +3.2% | -3.2% |
| Mar 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $17.56 | $10.58 | -39.7% | -52.7% | +8.8% | -5.3% | -1.4% | +3.2% |
| Mar 7 | Citigroup | Maintains | Neutral → Neutral | — | $18.06 | $17.97 | -0.5% | +1.2% | -3.9% | -52.7% | +8.8% | -5.3% |
| Feb 12 | BMO Capital | Maintains | Outperform → Outperform | — | $17.68 | $17.51 | -1.0% | +1.5% | -1.6% | +3.6% | +1.9% | -0.6% |
| Feb 12 | Guggenheim | Maintains | Buy → Buy | — | $17.68 | $17.51 | -1.0% | +1.5% | -1.6% | +3.6% | +1.9% | -0.6% |
| Feb 12 | Stifel | Maintains | Buy → Buy | — | $17.68 | $17.51 | -1.0% | +1.5% | -1.6% | +3.6% | +1.9% | -0.6% |
| Feb 12 | Oppenheimer | Maintains | Outperform → Outperform | — | $17.68 | $17.51 | -1.0% | +1.5% | -1.6% | +3.6% | +1.9% | -0.6% |
| Feb 7 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $19.10 | $19.11 | +0.1% | -2.1% | +1.4% | -6.8% | +1.5% | -1.6% |
| Feb 3 | Barclays | Maintains | Overweight → Overweight | — | $17.61 | $17.41 | -1.1% | -2.9% | +5.6% | +8.5% | -2.5% | -2.1% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Jun 24, 2026 | Saik AndrewOff | Chief Financial Officer | Sell | 5,696 | $8.16 | $46K | 187,432 | -0.25% | -1.32% |
| Jun 17, 2026 | Cacace Angela MOff | Chief Scientific Officer | Sell | 2,576 | $7.59 | $20K | 180,390 | +0.91% | -0.37% |
| May 11, 2026 | Saik AndrewOff | Chief Financial Officer | Sell | 11,139 | $9.94 | $111K | 193,128 | -4.56% | +6.43% |
| May 11, 2026 | Cacace Angela MOff | Chief Scientific Officer | Sell | 9,657 | $9.94 | $96K | 182,966 | -4.56% | +6.43% |
| May 11, 2026 | Berkowitz NoahOff | Chief Medical Officer | Sell | 11,108 | $9.94 | $110K | 191,395 | -4.56% | +6.43% |
| May 11, 2026 | Teel RandyDir/Off | President and CEO | Sell | 9,657 | $9.94 | $96K | 287,218 | -4.56% | +6.43% |
| May 11, 2026 | Loomis David KOff | VP, Chief Accounting Officer | Sell | 1,919 | $9.94 | $19K | 40,193 | -4.56% | +6.43% |
8-K · 2.02
!! High
Arvinas, Inc. -- 8-K 2.02: Earnings Results
Aug 4
8-K
Arvinas, Inc. -- 8-K Filing
I cannot provide a meaningful analysis based on this filing summary, as it appears to contain only boilerplate corporate formation and address information without substantive business developments or financial transactions relevant to investors.
Jun 25
8-K · 5.02
!!! Very High
Arvinas, Inc. -- 8-K 5.02: Executive Change
Arvinas loses its Chief Medical Officer Noah Berkowitz on July 3, 2026, which may impact clinical development strategy and investor confidence in the biotech firm's pipeline progress.
Jun 22
8-K · 8.01
!! High
Arvinas, Inc. -- 8-K 8.01: Material Event / Announcement
Arvinas' previously disclosed May 11, 2026 transaction with subsidiaries Arvinas Operations and Arvinas Estrogen Receptor appears to involve significant corporate restructuring affecting ARVN shareholders.
Jun 16
8-K · 8.01
!! High
Arvinas, Inc. -- 8-K 8.01: Material Event / Announcement
Arvinas is reprioritizing its drug pipeline after completing dose escalation in its Phase 1 KRAS G12D trial for ARV-806, signaling potential strategic shifts that could impact development timelines and resource allocation.
Jun 2
8-K · 2.02
!! High
Arvinas, Inc. -- 8-K 2.02: Earnings Results
Arvinas reported Q1 2026 financial results and provided a corporate update, though specific revenue and earnings figures require reviewing the detailed filing to assess operational performance and outlook.
May 12
8-K · 1.01
!! High
Arvinas, Inc. -- 8-K 1.01: Collaboration Agreement
May 12
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
Arvanium's ARV-102 achieved meaningful LRRK2 degradation in Parkinson's patients, validating its novel brain-penetrating PROTAC approach and potentially de-risking its pipeline for neurodegenerative disease treatment.
Mar 18
8-K
Arvinas, Inc -- 8-K Filing
Arvinas reported Q4 2025 results and submitted its first NDA for a PROTAC degrader drug candidate, positioning the company for potential FDA approval of this novel drug class while refocusing its pipeline strategy.
Feb 24
8-K · 5.02
!!! Very High
Arvinas, Inc -- 8-K 5.02: Executive Change
Arvinas appointed Briggs Morrison and Randy Teel as presidents while John Houston resigned, signaling potential leadership restructuring that investors should monitor for strategic direction changes.
Feb 12
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Vanguard Portfolio Management Llc | 3,889,628 | $41M | New | Mar 2026 |
| 2 | D.e. Shaw & Co | 3,638,567 | $39M | Reduced | Mar 2026 |
| 3 | Pfizer Inc | 3,457,815 | $35M | — | Mar 2026 |
| 4 | Vanguard Capital Management Llc | 2,689,362 | $29M | New | Mar 2026 |
| 5 | Two Sigma Investments, Lp | 1,832,114 | $19M | Added | Mar 2026 |
| 6 | Morgan Stanley | 1,620,144 | $19M | Reduced | Dec 2025 |
| 7 | Qube Research & Technologies Ltd | 1,201,635 | $13M | Reduced | Mar 2026 |
| 8 | Citadel Advisors Llc | 1,180,988 | $13M | Added | Mar 2026 |
| 9 | Acadian Asset Management Llc | 949,874 | $10M | Reduced | Mar 2026 |
| 10 | Tang Capital Management Llc | 569,698 | $7M | Reduced | Dec 2025 |
| 11 | Millennium Management | 576,352 | $6M | Reduced | Mar 2026 |
| 12 | Northern Trust Corp | 520,955 | $6M | Reduced | Mar 2026 |
| 13 | Nuveen, Llc | 406,340 | $4M | Added | Mar 2026 |
| 14 | Jane Street Group, Llc | 309,113 | $4M | Reduced | Dec 2025 |
| 15 | Invesco Ltd. | 316,654 | $3M | Added | Mar 2026 |
| 16 | Superstring Capital Management Lp | 312,620 | $3M | New | Mar 2026 |
| 17 | Aqr Capital Management Llc | 285,118 | $3M | Reduced | Mar 2026 |
| 18 | Hrt Financial Lp | 270,302 | $3M | Added | Mar 2026 |
| 19 | Caxton Associates Llp | 260,016 | $3M | Reduced | Mar 2026 |
| 20 | Nomura Holdings Inc | 253,609 | $3M | New | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$564.6M
Enterprise Value
-$117.1M
P/E (TTM)
60.71x
Forward P/E
—
PEG Ratio
0.18x
P/B
1.31x
P/S
1.78x
P/FCF
-2.06x
EV/EBITDA
-40.39x
Shares Out
64.9M
Financials (TTM)
Revenue
$316.7M
Net Income
$9.3M
EBITDA
$2.9M
Free Cash Flow
-$275.7M
Op Cash Flow
-$273.8M
EPS Basic
$-1.28
EPS Diluted
$0.16
EPS Forward
$-3.32
Gross Margin
96.4%
Op Margin
-4.5%
Net Margin
2.9%
Balance Sheet
Total Assets
$717.9M
Total Liab.
$284.0M
Total Equity
$433.9M
Cash
$685.4M
LT Debt
$400K
Book Value/Sh
$6.69
Debt/Equity
0.02x
Current Ratio
4.92
Quick Ratio
4.92
Returns & Growth
ROE
-18.6%
ROA
-11.3%
ROIC
-19.9%
Rev Growth YoY
-0.3%
EPS Growth YoY
+53.8%
Price Returns
2W
+9.0%
1M
+2.2%
3M
-13.5%
6M
-35.1%
12M
+39.1%
Technicals
52W High
$14.51
52W Low
$6.32
50d MA
$8.09
200d MA
$10.62
RSI (14)
62.30
ATR (14)
$0.38
Beta
1.98
Avg Volume
898K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$13.00
High
$18.00
Low
$10.00
Median
$11.00
Data updated apr 24, 2026 7:05pm
· Source: financialmodelingprep.com